Praxis Precision Medicines, Inc. PRAX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Program-specific expenses by Product | ||||||
| Elsunersen | $3.2M+320% | $2.54M+362% | $2.22M+484% | $1.32M+92.3% | $761K+46.1% | |
| Other early stage assets | $3.24M+193% | $2.36M+69.2% | $3.14M+166% | $1.42M+23.9% | $1.11M+20.2% | |
| Relutrigine | $12.85M+139% | $15.1M+447% | $14.97M+1,085% | $10.51M+744% | $5.38M+434% | |
| Ulixacaltamide | $19.1M-18.8% | $9.67M-62.8% | $11.64M-41.7% | $18.39M+52.6% | $23.51M+111% | |
| Vormatrigine | $20.49M+49.2% | $21.47M+135% | $20.9M+216% | $17.96M+865% | $13.73M+1,776% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Praxis Precision Medicines, Inc. break its business down?
- Praxis Precision Medicines, Inc. (PRAX) reports program-specific expenses by product across 5 parts — Elsunersen, Other early stage assets, Relutrigine, Ulixacaltamide and Vormatrigine. Each is extracted from the segment footnotes and tracked over time.
- Where does Praxis Precision Medicines, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Praxis Precision Medicines, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.